TARGETING UNIQUE TUMOR-SPECIFIC ANTIGENS TO SHIFT THE CANCER TREATMENT PARADIGM

OUR MISSION

Stromatis Pharma is committed to bringing life-saving therapeutics to patients suffering from difficult-to-treat cancers by combining highly specific targets with superior antibody-derived therapeutics. Using an innovative and proprietary antibody-discovery platform, we are expanding our treatment portfolio to address additional unmet patient needs.

SPECIFIC TARGETS AND SUPERIOR ANTIBODIES

Antibody-drug conjugate (ADC) therapies deliver toxic chemotherapies to tumor cells, not healthy tissue, making them “the next generation” of cancer treatment.

However, an ADC therapeutic is only as good as its target.

At Stromatis Pharma, we identified a unique epitope allowing targeting of both CEACAM5 and CEACAM6, receptors found exclusively on the membranes of certain cancer cells. We then used a proprietary antibody-discovery platform to create a superior antibody, CT109, which selectively binds to CEACAM5/6-expressing tumor cells. CT109 exhibits little to no binding to normal cells. When combined with a drug conjugate,

This translates to more effective, less toxic cancer treatments.

ADCs represent the next generation of cancer treatment, and we believe that CT109 is at the forefront of this therapeutic evolution.

At Stromatis Pharma, we are advancing ADC technology using specific targets and superior antibodies to bring life-saving therapeutics to cancer patients.

Antibody-drug conjugate (ADC) therapies deliver toxic chemotherapies to tumor cells, not healthy tissue, making them “the next generation” of cancer treatment.

However, an ADC therapeutic is only as good as its target.

At Stromatis Pharma, we identified a unique epitope allowing targeting of both CEACAM5 and CEACAM6, receptors found exclusively on the membranes of certain cancer cells. We then used a proprietary antibody-discovery platform to create a superior antibody, CT109, which selectively binds to CEACAM5/6-expressing tumor cells. CT109 exhibits little to no binding to normal cells. When combined with a drug conjugate,

this translates to more effective, less toxic cancer treatments.

ADCs represent the next generation of cancer treatment, and we believe that CT109 is at the forefront of this therapeutic evolution.

At Stromatis Pharma, we are advancing ADC technology using specific targets and superior antibodies to bring life-saving therapeutics to cancer patients.

Our Science

COLLABORATION / CO-DEVELOPMENT OF THERAPEUTICS

Stromatis Pharma is delivering cutting-edge antibody-derived therapeutics to the clinic. Our antibodies have the potential to be used for a number of indications and multiple treatment approaches. Given the diverse applicability of our technology, we utilize an extensive and expert network of collaborators, researchers, and investors to advance our therapeutic development. For inquiries regarding potential partnerships, contact us.

Pipeline